Crossignal Therapeutics
A clinical-stage biotechnology company focused on discovery and development of small-molecule immuno-oncology therapeutics that target tumor microenvironment‑expressed GPCRs (referred to as TMERs). The company pursues target identification, immune cell expression profiling, pathway elucidation, assay development, medicinal chemistry and early clinical development (Phase 1/2a) of candidates that modulate tumor immune escape pathways such as Hippo‑YAP and adenosine signaling.
Industries
Nr. of Employees
small (1-50)
Crossignal Therapeutics
La Jolla, California, United States, North America
Products
CT3001
A small‑molecule inhibitor targeting GPR35 (a TMER) designed to modulate Hippo‑YAP signaling and block IDO1‑mediated tumor immune escape; developed for GPR35+ IDO1+ solid tumors.
CT3021
A small‑molecule, highly potent triple antagonist of adenosine receptors (A2a, A2b, A1) developed for tumors with adenosine pathway activity; reported in IND‑enabling stage.
TMER3‑i
Discovery‑stage small‑molecule program against an undisclosed TMER aimed at modulating Hippo‑YAP to block tumor immune escape; at candidate nomination stage.
TMER4‑i
Early discovery small‑molecule program against an undisclosed TMER focused on Hippo‑YAP regulation; in hit‑to‑lead progression.
Small‑molecule PD‑1/PD‑L1 blocker (discovery)
Discovery‑stage small‑molecule program aimed at blocking PD‑1/PD‑L1 interaction for mono or combination immuno‑oncology use; currently in hit‑to‑lead stage.
CT3001
A small‑molecule inhibitor targeting GPR35 (a TMER) designed to modulate Hippo‑YAP signaling and block IDO1‑mediated tumor immune escape; developed for GPR35+ IDO1+ solid tumors.
CT3021
A small‑molecule, highly potent triple antagonist of adenosine receptors (A2a, A2b, A1) developed for tumors with adenosine pathway activity; reported in IND‑enabling stage.
TMER3‑i
Discovery‑stage small‑molecule program against an undisclosed TMER aimed at modulating Hippo‑YAP to block tumor immune escape; at candidate nomination stage.
TMER4‑i
Early discovery small‑molecule program against an undisclosed TMER focused on Hippo‑YAP regulation; in hit‑to‑lead progression.
Small‑molecule PD‑1/PD‑L1 blocker (discovery)
Discovery‑stage small‑molecule program aimed at blocking PD‑1/PD‑L1 interaction for mono or combination immuno‑oncology use; currently in hit‑to‑lead stage.
Expertise Areas
- Immuno‑oncology small‑molecule drug discovery
- GPCR target identification and validation
- Assay development for pathway‑focused GPCR screening
- Medicinal chemistry and SAR optimization
Key Technologies
- Small‑molecule therapeutics
- GPCR targeting
- Pathway‑precision screening assays
- Structure‑activity relationship (SAR) studies